Advertisement

Topics

[Articles] Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

19:59 EDT 3 Aug 2017 | The Lancet

Exenatide had positive effects on practically defined off-medication motor scores in Parkinson's disease, which were sustained beyond the period of exposure. Whether exenatide affects the underlying disease pathophysiology or simply induces long-lasting symptomatic effects is uncertain. Exenatide represents a major new avenue for investigation in Parkinson's disease, and effects on everyday symptoms should be examined in longer-term trials.

Original Article: [Articles] Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

NEXT ARTICLE

More From BioPortfolio on "[Articles] Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial"

Quick Search
Advertisement
 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...